| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2015: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
|
|---|
| Outline of Final Research Achievements |
We used multimodal approach to evaluate the effects of edaravone in a rat model of spinal cord injury (SCI). SCI was induced by extradural compression of the spinal cord at the thoracic level. Moderate-dose (3 mg/kg/h) edaravone was administered 30 min prior to compression, at the start of compression, or 10 min after decompression. Preemptive administration regimens resulted in significantly improved spinal motor-evoked potentials (MEPs). A moderate-dose of edaravone resulted in significant attenuation of lipid peroxidation, as evidenced by lower concentrations of free radical malonyldialdehyde (MDA) in the spinal cord at 3 h post-SCI. Both moderate- and high-dose edaravone resulted in significant functional improvements evidenced by better Basso-Beattie-Bresnahan (BBB) scores and better performance on the inclined plane during 8-wk period post-SCI.
|
